Related Experiment Videos
How does ticlopidine treatment lower plasma fibrinogen?
E Mazoyer1, L Ripoll, M R Boisseau
1Laboratoire d'Immuno-Hématologie, Hôpital Lariboisière, Paris, France.
Thrombosis Research
|August 1, 1994
Summary
Ticlopidine treatment shows a consistent trend in reducing plasma fibrinogen (Fg) levels by 10-25% across diverse vascular conditions. This reduction correlates with clinical improvements and favorable hemorheological changes.
Area of Science:
- Pharmacology
- Vascular Medicine
- Clinical Research
Background:
- Ticlopidine is evaluated for vascular pathology.
- Plasma fibrinogen (Fg) levels are inconsistently measured as a secondary endpoint.
- Existing studies on ticlopidine exhibit heterogeneity in methodology, patient inclusion, and follow-up duration.
Purpose of the Study:
- To synthesize findings on ticlopidine's effect on plasma fibrinogen (Fg) levels.
- To assess the association between Fg reduction and clinical outcomes.
- To explore hemorheological modifications linked to ticlopidine therapy.
Main Methods:
- Systematic review and trend analysis of heterogeneous clinical studies.
- Inclusion of patients with peripheral arterial disease, cerebrovascular disease, diabetes, and polycythemia vera.
- Analysis of plasma Fg levels measured via various methods over 1-24 months.
Main Results:
- A consistent trend of 10-25% decrease in plasma Fg levels with ticlopidine versus placebo.
- Observed association between decreased Fg and clinical improvement.
- Reported hemorheological modifications, including reduced blood and plasma viscosity.
Conclusions:
- Ticlopidine demonstrates a consistent effect in lowering plasma fibrinogen levels.
- The reduction in Fg is linked to improved clinical outcomes in vascular pathologies.
- Ticlopidine may exert beneficial effects through hemorheological modulation.